Response to letter to the editor PD-17-0390, a comment on “Comparing methods for fetal fraction determination and quality control of NIPT samples”

van Beek, Daphne M; Straver, Roy; Weiss, Marian M.; Boon, Elles M.J.; Huijsdens-van Amsterdam, Karin; Oudejans, Cees B.M.; Reinders, Marcel; Sistermans, Erik A.

DOI
10.1002/pd.5170

Publication date
2017

Document Version
Final published version

Published in
Prenatal Diagnosis

Citation (APA)

Important note
To cite this publication, please use the final published version (if applicable). Please check the document version above.

Copyright
Other than for strictly personal use, it is not permitted to download, forward or distribute the text or part of it, without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license such as Creative Commons.

Takedown policy
Please contact us and provide details if you believe this document breaches copyrights. We will remove access to the work immediately and investigate your claim.

This work is downloaded from Delft University of Technology. For technical reasons the number of authors shown on this cover page is limited to a maximum of 10.
Correspondence

Response to letter to the editor PD-17-0390, a comment on “Comparing methods for fetal fraction determination and quality control of NIPT samples”

In a recent edition of Prenatal Diagnosis, we published a comparison between bioinformatic methods that estimate the fetal cell-free DNA fraction in maternal plasma, which is essential knowledge when performing NIPT tests. Grendar et al confirmed the need for this paper, but commented on our findings by stating that we left data unexplored, mainly pointing towards observable biases between the different approaches (ie, deviation from the 45° line through the origin in pairwise comparisons). Clearly, these systematic differences can be observed (an updated figure showing this effect more clearly, as well as a table containing the underlying data are included as new supplementary data). However, since there is no gold standard available (ie, the true fetal fraction is unknown), nor is it (easily) faithfully extractable, it is not possible to confirm which bias is to be preferred. Therefore, we decided not to zoom in on this level of comparison, but to restrict to conclusions of a more general nature.

Mainly, we compared three methods: Y chromosome-based methods (DEFRAG, BAYINDIR), a different method based on all chromosomes (SeqFF), and one based on fragment lengths of the cell-free DNA (SANEFALCON). As Y-based methods for pregnancies with male fetuses are likely closest to the truth (due to the absence of the Y in the mother), looking at correlations with the no-Y-based methods makes sense (this is also not argued by Grendar et al). This comparison shows that the no-Y-based methods are more variable, and consequently have a lower correlation to the Y-based methods. Yet, in contrast to Y-based methods, they can still be used for pregnancies carrying female fetuses, as their correlation is still good (>0.9 for SeqFF). Within the Y-based methods, we also compared whether focusing on uniquely mapping male regions on Y would increase reliability (differences between the a/b methods for both DEFRAG and BAYINDIR). BAYINDIR is especially sensitive for this difference, with BAYINDIRa (not focusing on male regions) having the largest variations in addition to nonzero fetal fractions for female pregnancies. We therefore concluded that focusing on uniquely mappable Y regions is preferable. The correlation between DEFRAGb and BAYINDIRb is high (0.984), resulting in our main conclusion to use any Y-based method for male-pregnancies. Zooming in on the differences between both methods, we see a minor systematic difference, with DEFRAGb resulting in slightly higher estimates of the fetal fraction than BAYINDIRb (Figure 1 in our manuscript). As stated before, in the absence of a gold standard, there is no way to tell which one is better, which prompted us to the more general conclusion on using any Y-based method. Grendar et al, claim that these systematic differences (on the order of 2.5%) make a huge difference when used in the NIPT procedure. Granted, if we would have implied that the estimates are unbiased estimates of the real fractions, this

![Figure 1](https://example.com/fig1.png)

**FIGURE 1** The lower left part of the matrix shows our comparison of the 6 different methods to predict fetal fraction from single-read NGS data for 654 maternal blood plasma samples. Blue dots represent the male pregnancies; red dots, the female pregnancies. Gray and green dots represent male and female pregnancies of a failed run, which contained degraded fetal DNA. On the diagonal of the matrix, the correlations to BMI (B), weight (W), and the gestational age (G) are shown, respectively. A diagonal line has been included in all lower left panels to indicate systematic differences. The upper right part of the matrix shows the correlation between the 2 methods [Colour figure can be viewed at wileyonlinelibrary.com]
difference is important. But, we did not claim this. In fact, we argue that the remark by Grendar et al is deceptive. First, the difference is artificial (when not knowing the true values). Second, and more importantly, in practice one can easily adapt decision thresholds to these differences. For NIPT this would result in shifting the decision threshold with 2.5% between the two methods when deciding on having enough fetal DNA to reliably interpret NIPT results. Taken together; the claims we made are supported by the correlations; systematic biases are present as Grendar et al rightly pointed out, but they cannot be interpreted and can easily be accounted for in clinical practice; the accuracy of the estimates of the fetal fraction is not known due to lack of a gold standard, but for clinical practice this is not essential.

ORCID

Daphne M. van Beek  
http://orcid.org/0000-0002-8700-3858
Erik A. Sistermans  
http://orcid.org/0000-0001-7187-4563

Daphne M. van Beek1*  
Roy Straver1*  
Marjan M. Weiss1  
Elles M.J. Boon1,2  
Karin Huijsdens-van Amsterdam3  
Cees B.M. Oudejans3  
Marcel J.T. Reinders5  
Erik A. Sistermans1

1Department of Clinical Genetics, VU University Medical Center, Amsterdam, Amsterdam, The Netherlands
2Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands
3Department of Clinical Genetics, Academic Medical Center, Amsterdam, The Netherlands
4Department of Clinical Chemistry, VU University Medical Center Amsterdam, Amsterdam, The Netherlands
5Delft Bioinformatics Lab, Delft University of Technology, Delft, The Netherlands

Correspondence
E. A. Sistermans, Department of Clinical Genetics, VU University Medical Center Amsterdam, Amsterdam, The Netherlands.
Email: e.sistermans@vumc.nl

*Daphne M. van Beek and Roy Straver contributed equally to this work.

REFERENCES

SUPPORTING INFORMATION
Additional Supporting Information may be found online in the supporting information tab for this article.